Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By reducing prostaglandin synthesis, ibuprofen decreases inflammation, lowers the pain‑signal threshold, and resets the hypothalamic temperature set‑point, resulting in analgesic, anti‑inflammatory, and antipyretic actions.

The appropriate dose of Ibuprofen B. Braun is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other clinical factors. Healthcare providers follow local guidelines and product labeling to select the correct infusion rate and total daily amount.

Safety data for intravenous ibuprofen during pregnancy are limited, and the product is generally avoided unless the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as ibuprofen can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Ibuprofen B. Braun offers a well‑characterized safety profile and is often chosen for its balanced analgesic and antipyretic effects. Compared with ketorolac, another IV NSAID, ibuprofen generally has a lower risk of severe gastrointestinal bleeding but may require higher doses for equivalent analgesia. Choice depends on patient‑specific factors, including renal function and bleeding risk.

The product must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. Before administration, inspect the solution for particulate matter or discoloration. Use aseptic technique and follow institutional protocols for IV infusion.

Ibuprofen B. Braun is given as an intravenous infusion, typically diluted in compatible IV fluids and administered over a specified period as directed by the prescriber. The infusion rate and total daily dose are adjusted according to the patient’s clinical response and tolerability.

Serious adverse events include gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and thrombotic cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for signs of bleeding, renal dysfunction, or allergic reactions during therapy.

Ibuprofen B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe uncontrolled hypertension, advanced heart failure, and those with significant renal impairment. It should also be avoided in patients receiving certain anticoagulants unless the benefit outweighs the risk.